End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
15.16
CNY
|
-1.94%
|
|
-0.07%
|
-5.55%
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
10,203
|
8,853
|
21,822
|
13,607
|
12,853
|
-
|
Enterprise Value (EV)
1 |
10,203
|
8,853
|
21,822
|
13,607
|
12,853
|
12,853
|
P/E ratio
|
32.6
x
|
-20.8
x
|
67.5
x
|
50.2
x
|
32.3
x
|
29.2
x
|
Yield
|
-
|
-
|
-
|
1.25%
|
-
|
-
|
Capitalization / Revenue
|
4.03
x
|
4.67
x
|
-
|
5.21
x
|
4.12
x
|
3.74
x
|
EV / Revenue
|
4.03
x
|
4.67
x
|
-
|
5.21
x
|
4.12
x
|
3.74
x
|
EV / EBITDA
|
21,278,618
x
|
-39,290,303
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.54
x
|
2.55
x
|
-
|
3.15
x
|
2.98
x
|
2.7
x
|
Nbr of stocks (in thousands)
|
803,357
|
803,357
|
808,504
|
847,799
|
847,799
|
-
|
Reference price
2 |
12.70
|
11.02
|
26.99
|
16.05
|
15.16
|
15.16
|
Announcement Date
|
20-02-26
|
21-04-26
|
23-04-10
|
24-04-22
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2,532
|
1,896
|
-
|
2,611
|
3,120
|
3,432
|
EBITDA
|
479.5
|
-225.3
|
-
|
-
|
-
|
-
|
EBIT
|
380.6
|
-324.2
|
-
|
-
|
-
|
-
|
Operating Margin
|
15.03%
|
-17.1%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
378.9
|
-345.3
|
-
|
-
|
-
|
-
|
Net income
1 |
317.7
|
-426.6
|
322.1
|
263.3
|
401
|
443
|
Net margin
|
12.55%
|
-22.5%
|
-
|
10.08%
|
12.85%
|
12.91%
|
EPS
2 |
0.3900
|
-0.5300
|
0.4000
|
0.3200
|
0.4700
|
0.5200
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.2000
|
-
|
-
|
Announcement Date
|
20-02-26
|
21-04-26
|
23-04-10
|
24-04-22
|
-
|
-
|
Fiscal Period: December |
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
539.3
|
641.1
|
758
|
776
|
799
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0200
|
0.0600
|
0.1400
|
0.0900
|
0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24-04-22
|
24-04-22
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
7.99%
|
-11.3%
|
-
|
6.58%
|
9.7%
|
9.7%
|
ROA (Net income/ Total Assets)
|
5.94%
|
-
|
-
|
-
|
6.5%
|
6.5%
|
Assets
1 |
5,352
|
-
|
-
|
-
|
6,169
|
6,815
|
Book Value Per Share
2 |
4.990
|
4.330
|
-
|
5.100
|
5.090
|
5.620
|
Cash Flow per Share
2 |
0.3100
|
0.1700
|
-
|
0.2200
|
0.2500
|
0.2600
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-26
|
21-04-26
|
23-04-10
|
24-04-22
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -5.55% | 1.78B | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|